Foreign capital isn't just coming back to China — it's coming back through a different door. Less greenfield, more dealmaking. If your China strategy memo still assumes "entry = set up a WFOE," the buy-side playbook may already be a step ahead of it.
- 8 of China's 20 largest M&A deals in 2026 have a foreign buyer (three of them American) — against just 2 in the whole of 2025.
- Life sciences and technology account for roughly 45% of this year's deal value — capital is changing shape, not leaving.
- Where the licence, team and pipeline exist, buying beats a multi-year build.
- But acquisitions run gates greenfield never meets: merger control, national-security review, FX. Deals have been unwound after completion when those weren't cleared.
- For a board, the question is no longer "should we be in China?" but "build or buy — and what's the approval path behind this target?"
The shift is visible in the deal data. Of China's 20 largest M&A transactions in 2026, eight involve a foreign buyer — three of them American. In the whole of 2025, the figure was two. Life sciences and technology account for around 45% of this year's deal value. Where the licence, the team and the pipeline already exist, acquiring or partnering beats a three-year build. Three forces are driving it.
1. Policy is actively courting it
Recent action plans on foreign investment specifically flag smoother cross-border M&A procedures, and the M&A rules under the Foreign Investment Law framework are being amended — including simpler cross-border share swaps. The direction of travel is toward making deals easier, not harder.
2. The targets have changed
Life sciences and technology now account for roughly 45% of this year's deal value, and the marquee transactions increasingly take the shape of licensing partnerships and stakes rather than sprawling, capital-heavy greenfield projects. The headline FDI number can mislead here: in the January–April 2026 official data, utilised foreign investment was down 10.3% year on year, yet high-technology industries made up 40.4% of it, and 20,113 new foreign-invested enterprises were established — up 6.8%. Capital isn't leaving China — it's changing shape, toward focused bets on technology, R&D and services.
3. Buying is faster than building
In sectors where the licence, team and pipeline already exist, acquiring or partnering gets you to market in a fraction of the time a greenfield entry would take. For many boards weighing a China move, "buy" has quietly become the faster route than "build."
The caveat: the doorway is still narrow
An acquisition runs through gates a greenfield entry never meets — merger control, national-security review, and foreign-exchange approvals. Deals have been unwound after completion when those gates weren't cleared. The door is more open than it was; the doorway is still narrow, and it's the approvals that decide whether a deal holds.
For foreign companies re-examining China in 2026, the practical takeaway is to run build-vs-buy as a real comparison — and, on the buy-side, to map merger control, security review and FX at the top of the process, not the end of it.
Frequently asked questions
Often, yes — where the licence, team and pipeline already exist, buying can beat a multi-year greenfield build. But an acquisition adds regulatory gates (merger control, security review, FX) that a fresh setup doesn't, so the timing advantage depends on clearing those cleanly.
Typically merger control, national-security review, foreign-investment filings and foreign-exchange registration — mapped and sequenced early, because deals can be unwound if those gates aren't cleared.
Sources
- White & Case M&A Explorer — China rising: how cross-border deals and Beijing's reform push are reviving the M&A landscape (9 June 2026) — foreign-buyer share of the top 20 deals; life sciences and technology share of deal value.
- MOFCOM — foreign investment statistics — utilised foreign investment and high-technology share (January–April 2026 basis; H1 figures not yet published at the time of writing).
This article is general information for foreign companies, not legal advice on any specific matter. Rules and practice change; please take advice on your facts.